Aldo-Keto Reductase (AKR) 1C3 Inhibitors: A Patent Review

    September 2017 in “ Expert opinion on therapeutic patents
    T.M. Penning
    Studysummary This review examines the patent literature on AKR1C3 inhibitors and suggests that although numerous potent inhibitors exist, further preclinical optimization is necessary before assessing their therapeutic potential in human diseases.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on europepmc.org →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Overexpression of Aldo-Keto Reductase 1C3 in LNCaP Cells Diverts Androgen Metabolism Towards Testosterone Resulting in Resistance to the 5α-Reductase Inhibitor Finasteride The Journal of Steroid Biochemistry and Molecular Biology · 2012